Business Context and Reporting Period
This Form 8-K Current Report was filed by AIT Therapeutics, Inc. (a Delaware corporation) on June 15, 2017, reporting events that occurred on June 13, 2017. The registrant is an emerging growth company based in Ness Ziona, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The Board of Directors executed significant changes to the Company's executive leadership effective June 13, 2017:
- Appointment of CEO: Mr. Steven A. Lisi was appointed as Chief Executive Officer.
- Role Transition: Mr. Amir Avniel stepped down as CEO but continues to serve as President and was additionally appointed as Chief Operating Officer.
- Board Continuity: Both Mr. Lisi and Mr. Avniel continue to serve as directors.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The document states that there are no arrangements or understandings regarding the selection of these officers other than those described or incorporated by reference from the Company's Form S-1 registration statement.
Investor Verification Checklist
- Verify the biographical details and compensation arrangements for Mr. Steven A. Lisi and Mr. Amir Avniel in the Company's Form S-1 (File No. 333-216287).
- Confirm the strategic rationale for the leadership transition between the CEO and COO roles.
- Review the Company's Form S-1 for any related party transactions involving the new officers.